The first human studies using humanized antibodies targeting IL‐31RA, the ligand‐binding subunit of the heterodimeric IL‐31 receptor complex, showed that blocking IL‐31 signaling significantly improves pruritus in patients with atopic eczema [8, 9, 10]. The gene discussed is IL31; the disease is atopic eczema.